Pegaspargase is under clinical development by Les Laboratoires Servier and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pegaspargase’s likelihood of approval (LoA) and phase transition for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) took place on 25 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pegaspargase Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pegaspargase overview

Pegaspargase (Oncaspar) is a modified version of the enzyme L-asparaginase, derived from E.coli, acts as anti-neoplastic agent. The product is based on customized PEGylation linker technology. It is formulated as pegylated injectable solution and lyophilized powder for intramuscular and intravenous route of administration. It is used for the first line treatment of acute lymphoblastic leukemia (ALL) as well as for the treatment of acute lymphoblastic leukemia in patients hypersensitive to native forms of L-asparaginase, in conjunction with other chemotherapeutic agents. Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. Pegaspargase was under development for the treatment of chronic myeloid leukemia, solid tumors, relapsed or refractory T-cell lymphomas and lymphomas including non-Hodgkin lymphoma.

The drug candidate is under development for the treatment of B cell acute lymphoblastic leukemia, malignant lymphoma, down syndrome, B lineage lymphoblastic lymphoma.

The drug candidate (freeze dried) was under development for the treatment  T-Cell lymphomas and chronic myelocytic leukemia.

Les Laboratoires Servier overview

Les Laboratoires Servier (Servier) researches, develops, manufactures and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders and others. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs). The company also provides generic drugs and contract development and manufacturing services across its global network. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, France.

Quick View Pegaspargase LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Pegaspargase
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.